GENELUX
Genelux Corporation is a privately-held, clinical stage biopharmaceutical company that has developed a proprietary oncolytic virus based technology platform and a deep pipeline of products with broad applications for cancer detection and therapy. GL-ONC1 the company’s lead oncology product candidate is an attenuated vaccina virus (Lister strain) that results in dramatic regression and elimination of a wide range of solid tumors in animals without damaging healthy tissues or organs. GL-ONC1 ... encodes Green Fluorescent Protein (GFP) to enable highly selective imaging of tumors and metastases as an aid in the diagnosis and staging of cancer. GL-ONC1 currently under evaluation in Phase I/II human clinical trials in the United States and Europe, and additional US and European-based trials are set to begin in the near future. GL-ONC1 is proving well-tolerated with minimal side effects and showing early signs of anti-tumor activity.
GENELUX
Industry:
Biopharma Biotechnology Health Diagnostics
Founded:
2001-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.genelux.com
Total Employee:
11+
Status:
Active
Contact:
8584830026
Email Addresses:
[email protected]
Total Funding:
20.48 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Current Employees Featured
Founder
Investors List
Woodward Diversified Capital
Woodward Diversified Capital investment in Convertible Note - Genelux
Official Site Inspections
http://www.genelux.com Semrush global rank: 5.66 M Semrush visits lastest month: 1.49 K
- Host name: hwsrv-453764.hostwindsdns.com
- IP address: 23.254.134.180
- Location: Seattle United States
- Latitude: 47.4902
- Longitude: -122.3004
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98168
More informations about "Genelux"
Genelux Corporation | Company
Build our organization into a fully integrated therapeutics company. Facilities. ... Genelux Corporation is committed to developing safe and effective next-generation immunotherapies …See details»
Genelux Corporation - Wikipedia
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or …See details»
Genelux - Crunchbase Company Profile & Funding
Organization. Genelux . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Genelux is a …See details»
Redefining Immuno-Oncology for Ovarian Cancer - Genelux …
Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor …See details»
News Releases - Genelux Corporation
Nov 6, 2024 WESTLAKE VILLAGE, Calif. , Oct. 09, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today …See details»
Genelux Corporation Company Profile | Westlake Village, CA ...
Find company research, competitor information, contact details & financial data for Genelux Corporation of Westlake Village, CA. Get the latest business insights from Dun & Bradstreet.See details»
Genelux Corporation Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Genelux Corporation of Redlands, CA. Get the latest business insights from Dun & Bradstreet.See details»
Genelux (GNLX) Company Profile & Description - Stock Analysis
Jan 26, 2023 Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in …See details»
Genelux Corporation Announces New Chief Financial …
Jan 30, 2025 WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined …See details»
Our Program - Genelux Corporation
Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our goal is to ensure access to our investigational …See details»
Genelux - Contacts, Employees, Board Members, Advisors & Alumni
Genelux is a biopharmaceutical company that develops diagnostic and therapeutic solutions for cancer and inflammatory diseases. ... Pricing. Log In. Log In. Experience the new Crunchbase, …See details»
Genelux Corporation (GNLX) - Yahoo Finance Canada
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or …See details»
Genelux Corporation Announces Pricing of $10.5 Million …
1 day ago WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, …See details»
Genelux 2025 Company Profile: Stock Performance & Earnings
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from …See details»
Genelux Corporation Announces $33 Million Private Placement
May 15, 2023 Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from …See details»
Pipeline - Genelux Corporation
Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor …See details»
Genelux Aligns With FDA On Approval Pathway For Olvi-Vec In
1 day ago Genelux is advancing Olvi-Vec with the goal of improving outcomes for patients with this difficult-to-treat disease. GNLX is trading at $3.11 down by 19.51 percent on the Nasdaq.See details»
Genelux Corporation to Participate in a Fireside Chat with H.C ...
Dec 13, 2024 WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today …See details»
Genelux prices 3M shares at $3.50 in underwritten public offering
1 day ago Genelux (GNLX) prices 3M shares at $3.50 each, raising $10.5M for clinical development & growth. Offering closes March 26, 2025.See details»
Technology - Genelux Corporation
Genelux Corporation is committed to developing safe and effective next-generation immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor …See details»